Sung‐Young Shin

Network topology dictates sequential drug efficacy through bistability-mediated state switching

The paper identifies network topology principles that determine sequential drug efficacy through bistability-mediated state switching.

Ribosomal Biogenesis Hyperactivation and ErbB signalling Mediated Network Rewiring Causes Adaptive Resistance to FGFR2 Inhibition

This study identifies ribosomal biogenesis hyperactivation and ErbB signaling reactivation as mechanisms of resistance to FGFR2 inhibitors in breast cancer cells and shows synergy with MEK inhibitors.

GeneSurv: Multi-Gene Cancer Survival Analysis Tool

GeneSurv enables multi-gene cancer survival analysis by correlating gene expression with patient outcomes, demonstrating its utility in identifying prognostic gene associations in breast cancer.

SynDISCO: A Mechanistic Modeling-Based Framework for Predictive Prioritization of Synergistic Drug Combinations Directed at Cell Signaling Networks

SynDISCO uses mechanistic ODE modeling to predict synergistic drug combinations targeting signaling networks, demonstrated on EGFR-MET in triple negative breast cancer.

Systematic Analysis of Network-driven Adaptive Resistance to CDK4/6 and Estrogen Receptor Inhibition using Meta-Dynamic Network Modelling

This paper develops a novel MDN modelling technique to study how heterogeneity influences adaptive resistance to CDK4/6 and estrogen receptor inhibitors through protein signalling dynamics.

Integrative Modelling of Signalling Network Dynamics Identifies Cell Type-selective Therapeutic Strategies for FGFR4-driven Cancers

The paper develops a computational model of FGFR4 signalling to identify cell type-selective combination therapies for FGFR4-driven cancers, revealing AKT and ERK reactivation as key resistance mechanisms.

Dynamic modelling of the PI3K/mTOR signalling network uncovers biphasic dependence of mTORC1 activation on the mTORC2 subunit Sin1

The paper uses computational models and experiments to show mTORC1 activity depends biphasically on mTORC2 subunit Sin1 and highlights mLST8 as a therapeutic target in breast cancer.